Infinity Pharmaceuticals, Inc. INFI today announced updated
Phase 1 data from an ongoing study of IPI-145, its potent, oral
inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in
patients with relapsed/refractory chronic lymphocytic leukemia (CLL), a
potentially fatal hematologic malignancy, or blood cancer. Data from the
study showed that IPI-145 was well tolerated, with a rapid onset of
clinical activity. These findings were presented today at the 2013
American Society of Clinical Oncology (ASCO) Annual Meeting. Based on
the tolerability and activity profile of IPI-145 observed to date,
Infinity also today announced that it has initiated a new expansion
cohort within its ongoing Phase 1 study to evaluate the safety, activity
and pharmacokinetics (PK) of IPI-145 dosed at 25 mg twice daily (BID) as
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in